Next 10 |
2023-07-17 10:52:03 ET Novan ( NASDAQ: NOVN ) shares plummeted -68.7% on Monday after the company said it had filed for bankruptcy and entered into a deal to sell most of its assets to Ligand Pharmaceuticals ( NASDAQ: LGND ) for $15 million. The company said tha...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
2023-06-01 10:10:21 ET Novan ( NASDAQ: NOVN ) will restructure its commercial business, impacting 39 employees, resulting in a reduction of ~50% of employees, primarily among its field sales representatives. The company estimates that it will incur ~$0.9M in charges rel...
2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...
2023-05-15 15:07:06 ET Novan, Inc. (NOVN) Q1 2023 Earnings Conference Call May 15, 2023 08:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive Vice President & Chief Operating Officer ...
2023-05-15 06:49:42 ET Novan press release ( NASDAQ: NOVN ): Q1 GAAP EPS of -$0.54 misses by $0.22 . Revenue of $3.17M (+66.8% Y/Y) misses by $3.02M . For further details see: Novan GAAP EPS of -$0.54 misses by $0.22, revenue of $3.17M misses by $3.02M
– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C...
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15 th . Novan management will host a conference call and live audio web...
News, Short Squeeze, Breakout and More Instantly...
Novan Inc. Company Name:
NOVN Stock Symbol:
NASDAQ Market:
-45.38% G/L:
$0.0941 Last:
7,190,009 Volume:
$0.1368 Open:
$0.0941 Close:
Novan Inc. Website:
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...